目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 List of key secondary sources
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key objectives of primary research
2.1.2.2 List of primary sources
2.1.2.3 Key data from primary sources
2.1.2.4 Breakdown of primary interviews
2.1.2.5 Insights from industry experts
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Revenue estimation of key players
2.2.1.2 Study of annual reports and investor presentations
2.2.1.3 Primary interviews
2.2.1.4 Growth forecast
2.2.1.5 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
2.4 STUDY ASSUMPTIONS
2.4.1 RESEARCH-RELATED ASSUMPTIONS
2.4.2 PARAMETRIC ASSUMPTIONS
2.4.3 GROWTH-RATE ASSUMPTIONS
2.4.4 MARKET ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN NEUROMODULATION MARKET
4.2 ASIA PACIFIC: NEUROMODULATION MARKET, BY END USER AND COUNTRY, 2024
4.3 NEUROMODULATION MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
4.4 NEUROMODULATION MARKET: REGIONAL MIX

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of neurological disorders and nerve injuries
5.2.1.2 High incidence of neurological disorders among geriatric population
5.2.1.3 Favorable government support and funding with advanced healthcare infrastructure
5.2.1.4 Development of advanced neuromodulation and neurostimulation technologies
5.2.1.5 Growing collaborations among device manufacturers, healthcare providers, and research institutions
5.2.1.6 Availability of reimbursements for neuromodulation devices
5.2.2 RESTRAINTS
5.2.2.1 High cost of neuromodulation procedures
5.2.2.2 Preference for drug therapies over neuromodulation products
5.2.2.3 Adverse effects and complications with neuromodulation devices
5.2.3 OPPORTUNITIES
5.2.3.1 Large population and high healthcare expenditure in emerging economies
5.2.3.2 Widening application scope of neuromodulation
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices
5.2.4.2 Shortage of trained professionals
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY STIMULATION TYPE, 2023-2025
5.4.2 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY KEY PLAYER, 2023-2025
5.4.3 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY REGION, 2023-2025
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT & FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Transcutaneous electrical nerve stimulation
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Wearable biosensors
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Regenerative medicine and stem cells
5.10 PATENT ANALYSIS
5.10.1 LIST OF KEY PATENTS
5.11 TRADE DATA ANALYSIS
5.11.1 IMPORT DATA FOR HS CODE 901890
5.11.2 EXPORT DATA FOR HS CODE 901890
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 CASE STUDY ANALYSIS
5.13.1 USE OF NEURALMODULATION TECHNOLOGIES IN RESEARCH, CLINICAL PRACTICE, AND CONSUMER APPLICATIONS
5.13.2 PAIRING TRANSLINGUAL NEUROSTIMULATION WITH INTENSIVE REHABILITATION TO ENHANCE NEUROPLASTICITY AND IMPROVE MOTOR RECOVERY IN SEVERE TRAUMATIC BRAIN INJURY PATIENTS
5.13.3 APPLICATION OF NEUROMODULATION TECHNIQUES-FROM NON-INVASIVE BRAIN STIMULATION TO DEEP BRAIN STIMULATION
5.14 REGULATORY ANALYSIS
5.14.1 REGULATORY LANDSCAPE
5.14.1.1 North America
5.14.1.1.1 US
5.14.1.1.2 Canada
5.14.1.2 Europe
5.14.1.3 Asia Pacific
5.14.1.3.1 China
5.14.1.3.2 Japan
5.14.1.3.3 India
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.15 PORTER'S FIVE FORCES ANALYSIS
5.15.1 BARGAINING POWER OF SUPPLIERS
5.15.2 BARGAINING POWER OF BUYERS
5.15.3 THREAT OF NEW ENTRANTS
5.15.4 THREAT OF SUBSTITUTES
5.15.5 INTENSITY OF COMPETITIVE RIVALRY
5.16 KEY STAKEHOLDERS & BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.16.2 KEY BUYING CRITERIA
5.17 IMPACT OF AI/GEN AI ON NEUROMODULATION MARKET
5.17.1 INTRODUCTION
5.17.2 POTENTIAL OF AI
5.17.3 IMPACT OF AI
5.17.4 KEY COMPANIES IMPLEMENTING AI
5.17.5 FUTURE OF AI
5.18 IMPACT OF 2025 US TARIFF ON NEUROMODULATION MARKET
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 IMPACT ON COUNTRY/REGION
5.18.4.1 North America
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.5 IMPACT ON END-USE INDUSTRIES
5.18.5.1 Hospitals

6 NEUROMODULATION MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
6.2 INTERNAL NEUROMODULATION
6.2.1 INTERNAL NEUROMODULATION TO RESULT IN BETTER TREATMENT RESULTS AND LOWER HEALTHCARE COSTS
6.3 EXTERNAL NEUROMODULATION
6.3.1 RISING DEMAND FOR NON-INVASIVE SOLUTIONS FOR NEUROLOGICAL AND PAIN-RELATED DISORDERS TO FUEL GROWTH

7 NEUROMODULATION MARKET, BY STIMULATION TYPE
7.1 INTRODUCTION
7.2 SPINAL CORD STIMULATION
7.2.1 GROWING INCIDENCE OF SPINAL CORD INJURIES TO FUEL MARKET GROWTH
7.3 DEEP BRAIN STIMULATION
7.3.1 MINIMALLY INVASIVE DEEP BRAIN STIMULATION TO DELIVER CONTROLLED ELECTRICAL IMPULSES AND REDUCE SIDE EFFECTS
7.4 SACRAL NERVE STIMULATION
7.4.1 INCREASING PREVALENCE OF CHRONIC URINARY INCONTINENCE AMONG ELDERLY WOMEN TO PROPEL MARKET GROWTH
7.5 VAGUS NERVE STIMULATION
7.5.1 RISING INCIDENCE OF EPILEPSY TO DRIVE ADOPTION OF NEXT-GENERATION VAGUS NERVE STIMULATION THERAPY
7.6 GASTRIC NERVE STIMULATION
7.6.1 INCREASING PREVALENCE OF GASTROESOPHAGEAL REFLUX DISEASE AND GASTROPARESIS TO FUEL MARKET GROWTH
7.7 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION
7.7.1 LOW COST AND EASE OF USE TO FUEL ADOPTION IN HEALTHCARE SECTOR
7.8 TRANSCRANIAL MAGNETIC STIMULATION
7.8.1 MINIMAL PATIENT DISCOMFORT ASSOCIATED WITH TRANSCRANIAL MAGNETIC STIMULATION TO SUPPORT DEMAND
7.9 RESPIRATORY ELECTRICAL STIMULATION
7.9.1 HIGH TREATMENT EFFICACY AND INCREASED FOCUS ON MINIMALLY INVASIVE SPINAL CORD TREATMENT TO FUEL MARKET GROWTH
7.10 OTHER STIMULATION TYPES

8 NEUROMODULATION MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION
8.2.1 CHRONIC PAIN
8.2.1.1 High incidence of chronic pain among geriatric population to support market growth
8.2.2 FAILED BACK SURGERY SYNDROME
8.2.2.1 Increasing number of spinal surgeries to aid market growth
8.2.3 ISCHEMIA
8.2.3.1 High effectiveness of neuromodulation to boost effectiveness for ischemia treatment
8.3 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION
8.3.1 PARKINSON'S DISEASE
8.3.1.1 Development of advanced solutions and increased R&D to improve market growth
8.3.2 TREMORS
8.3.2.1 Increased prevalence of tremors and high efficacy of deep brain stimulation to drive market
8.3.3 DEPRESSION
8.3.3.1 Ongoing research and clinical studies to boost adoption of deep brain stimulation for depression treatment
8.3.4 OTHER DEEP BRAIN STIMULATION APPLICATIONS
8.4 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION
8.4.1 URINE INCONTINENCE
8.4.1.1 High incidence of urine incontinence to offer growth opportunities for market players
8.4.2 FECAL INCONTINENCE
8.4.2.1 Reduced symptom recurrence with sacral nerve stimulation to aid long-term management of fecal incontinence
8.5 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION
8.5.1 EPILEPSY
8.5.1.1 Low risk with device implantation and long-lasting battery life to aid market growth
8.5.2 OTHER VAGUS NERVE STIMULATION APPLICATIONS
8.6 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION
8.6.1 GASTROPARESIS
8.6.1.1 Reduced hospitalization time associated with sastroparesis treatment to augment market growth
8.6.2 OBESITY
8.6.2.1 High prevalence of obesity and risks associated with gastric bypass to propel market growth
8.7 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION
8.7.1 TREATMENT-RESISTANT DEPRESSION
8.7.1.1 High prevalence of chronic and recurrent depression to augment market growth
8.7.2 OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS
8.8 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION
8.8.1 DEPRESSION
8.8.1.1 Repeated transcranial magnetic stimulation to be well-tolerated procedure with improved acceptance among patients
8.8.2 MIGRAINE
8.8.2.1 High prevalence of migraines to support market growth
8.9 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY APPLICATION
8.9.1 INCREASING INCIDENCE OF SPINAL CORD INJURIES TO ENSURE CONTINUED DEMAND FOR ADVANCED TREATMENT OPTIONS
8.10 OTHER APPLICATIONS

9 NEUROMODULATION MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS & AMBULATORY SURGERY CENTERS
9.2.1 ADVANCED INFRASTRUCTURE AND ABILITY TO MANAGE COMPLEX NEUROLOGICAL CASES TO PROPEL MARKET GROWTH
9.3 CLINICS & PHYSIOTHERAPY CENTERS
9.3.1 NEED FOR FOCUSED EXPERTISE AND BETTER REHABILITATION MANAGEMENT TO ACCELERATE MARKET EXPANSION
9.4 OTHER END USERS

10 NEUROMODULATION MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 US to dominate North American neuromodulation market during forecast period
10.2.3 CANADA
10.2.3.1 Increasing neurological disorder rates and rising government funding to propel market growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Advanced surgical innovations and favorable reimbursement policies to drive market
10.3.3 FRANCE
10.3.3.1 Favorable healthcare reforms to drive adoption of advanced neuromodulation techniques
10.3.4 UK
10.3.4.1 Increased public & private sector healthcare expenditure and investments to fuel market growth
10.3.5 ITALY
10.3.5.1 Rising cases of dementia and Alzheimer's among geriatric population to spur market growth
10.3.6 SPAIN
10.3.6.1 Favorable government-led healthcare initiatives to support market growth
10.3.7 RUSSIA
10.3.7.1 Shifting demographic landscape and escalating neurological health needs to drive demand
10.3.8 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Government-led healthcare reforms and high prevalence of neurological disorders to fuel demand
10.4.3 JAPAN
10.4.3.1 Innovative healthcare delivery and advanced infrastructure landscape to augment market growth
10.4.4 INDIA
10.4.4.1 Booming medical tourism and rising middle class with higher disposable incomes to accelerate market growth
10.4.5 AUSTRALIA
10.4.5.1 Increasing cases of depressive and post-traumatic stress disorders to propel market demand
10.4.6 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Improvements in healthcare infrastructure to aid market growth
10.5.3 MEXICO
10.5.3.1 Expanding healthcare awareness and growing burden of neurological disorders to favor market growth
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE AND INCREASED AWARENESS OF NEUROLOGICAL CARE TO DRIVE MARKET
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NEUROMODULATION MARKET
11.3 REVENUE ANALYSIS, 2020-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.5.5.1 Company footprint
11.5.5.2 Region footprint
11.5.5.3 Technology footprint
11.5.5.4 Stimulation type footprint
11.5.5.5 End-user footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.6.5.1 Detailed list of key startups/SMEs
11.6.5.2 Competitive benchmarking of startups/SMEs
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.7.1 COMPANY VALUATION
11.7.2 FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES & APPROVALS
11.9.2 DEALS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 MEDTRONIC
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Product approvals
12.1.1.4 MnM view
12.1.1.4.1 Right to win
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 BOSTON SCIENTIFIC CORPORATION
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.3.1 Product approvals
12.1.2.3.2 Deals
12.1.2.4 MnM view
12.1.2.4.1 Right to win
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 ABBOTT
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.3.1 Product launches and approvals
12.1.3.4 MnM view
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 LIVANOVA PLC
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Product launches
12.1.4.4 MnM view
12.1.4.4.1 Right to win
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses & competitive threats
12.1.5 NEVRO CORP.
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Product approvals
12.1.5.3.2 Deals
12.1.5.4 MnM view
12.1.5.4.1 Right to win
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses & competitive threats
12.1.6 NEUROPACE, INC.
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.7 BIOVENTUS
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.7.3.1 Product approvals
12.1.8 ELECTROCORE, INC.
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.8.3 Recent developments
12.1.8.3.1 Product launches
12.1.8.3.2 Deals
12.1.9 HELIUS MEDICAL TECHNOLOGIES, INC.
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.9.3 Recent developments
12.1.9.3.1 Deals
12.1.10 NEURONETICS
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.10.3 Recent developments
12.1.10.3.1 Product approvals
12.1.10.3.2 Deals
12.2 OTHER PLAYERS
12.2.1 NEUROSIGMA, INC.
12.2.2 SOTERIX MEDICAL INC.
12.2.3 SYNAPSE BIOMEDICAL INC.
12.2.4 ALEVA NEUROTHERAPEUTICS
12.2.5 THERANICA BIO-ELECTRONICS LTD.
12.2.6 GIMER MEDICAL
12.2.7 NALU MEDICAL, INC.
12.2.8 MICROTRANSPONDER INC.
12.2.9 MAGSTIM
12.2.10 AMBER THERAPEUTICS
12.2.11 TVNS TECHNOLOGIES GMBH
12.2.12 BIOWAVE
12.2.13 BIOTRONIK
12.2.14 SALUDA MEDICAL PTY LTD.
12.2.15 SPR

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS